7 years ago

AdoRx Therapeutics Raises $10M to Develop New Cancer Therapies

  • AdoRx Therapeutics, a UK-based drug discovery company, has secured $10 million in initial funding led by Epidarex Capital and CRT Pioneer Fund

  • AdoRx is developing new cancer therapies by modulating the adenosine pathway, targeting high adenosine levels in the tumor microenvironment with adenosine receptor antagonists

  • The company was founded in 2017 and is led by CEO Pete Finan, former head of the Novartis Institutes of BioMedical Research UK

  • The funding will be used to further develop AdoRx's drug candidates.

      • ProblemHealthcare

      "Cancer cells can evade the immune system by creating high levels of adenosine in the tumor microenvironment, which makes it difficult for the body to fight the cancer."

      Solution

      "AdoRx Therapeutics is developing adenosine receptor antagonists to overcome the effects of high adenosine levels and allow the immune system to fight cancer more effectively."

      Covered on